Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Tabara, Keisuke ^a   Kanda, Rina ^a   Sonoda, Kahori ^a   Kubo, Takuya ^a   Murakami, Yuichi ^a,b   Kawahara, Akihiko ^c   Azuma, Koichi ^d   Abe, Hideyuki ^c   Kage, Masayoshi ^c   Yoshinaga, Aki ^a   Tahira, Tomoko ^a   Hayashi, Kenshi ^a   Arao, Tokuzo ^e   Nishio, Kazuto ^e   Rosell, Rafael ^f,g   Kuwano, Michihiko ^a   Ono, Mayumi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b ST MARY S HOSPITAL   (Japan)

^c KURUME UNIVERSITY HOSPITAL   (Japan)

^d KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e KINKI UNIVERSITY   (Japan)

^f HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^g INSTITUT UNIVERSITARI DEXEUS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; LAPATINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG RESISTANCE; DRUG SENSITIVITY; EGFR GENE; ENZYME ACTIVATION; GENE; GENE LOSS; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; LUNG CANCER; MUTANT; SIGNAL TRANSDUCTION;

ALLELES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LUNG NEOPLASMS; MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84864015211     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041017     Document Type: Article

References (39)

1. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, et al. (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26: 127-32.
2. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21: 2237-46.
3. Perez-Sole R, (2004) The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer. Clin Cancer Res 10: 4238s-40s.
4. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-32.
5. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-39.
6. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-500.
7. Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-11.
8. Sharma SV, Bell DW, Settleman J, Haber DA, (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169-81.
9. Sharma SV, Haber DA, Settleman J, (2010) Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer 10: 241-53.
10. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, et al. (2005) Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23: 2513-20.
11. Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, et al. (2005) EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23: 857-65.
12. Inoue A, Suzuki T, Fukuhara T, Maemondo M, Kimura Y, et al. (2006) Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 24: 3340-6.
13. Riely GJ, Politi KA, Miller VA, Pao W, (2006) Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 12: 7232-41.
14. Ono M, Hirata A, Kometani T, Miyagawa M, Ueda S, et al. (2004) Sensitivity to gefitinib (iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther 3: 465-72.
15. Ono M, Kuwano M, (2006) Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 12: 7242-51.
16. Hammerman PS, Janne PA, Johnson BE, (2009) Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 15: 7502-9.
17. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-92.
18. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73.
19. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-43.
20. Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, et al. (2008) Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 68: 9479-87.
21. Yamamoto C, Basaki Y, Kawahara A, Nakashima K, Kage M, et al. (2010) Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. Cancer Res 70: 8715-25.
22. Uramoto H, Shimokawa H, Hanagiri T, Kuwano M, Ono M, (2011) Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma. Lung Cancer 73: 361-5.
23. Baba S, Kukita Y, Higasa K, Tahira T, Hayashi K, (2003) Single-stranded conformational polymorphism analysis using automated capillary array electrophoresis apparatuses. Biotechniques 34: 746-50.
24. Tahira T, Baba S, Higasa K, Kukita Y, Suzuki Y, et al. (2005) dbQSNP: a database of SNPs in human promoter regions with allele frequency information determined by single-strand conformation polymorphism-based methods. Hum Mutat 26: 69-77.
25. Kukita Y, Higasa K, Baba S, Nakamura M, Manago S, et al. (2002) A single-strand conformation polymorphism method for the large-scale analysis of mutations/polymorphisms using capillary array electrophoresis. Electrophoresis 23: 2259-66.
26. Tahira T, Okazaki Y, Miura K, Yoshinaga A, Masumoto K, et al. (2006) QSNPlite, a software system for quantitative analysis of SNPs based on capillary array SSCP analysis. Electrophoresis 27: 3869-78.
27. Kawahara A, Yamamoto C, Nakashima K, Azuma K, Hattori S, et al. (2010) Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis. Clin Cancer Res 16: 3163-70.
28. Kawahara A, Azuma K, Sumi A, Taira T, Nakashima K, et al. (2011) Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: Rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry. Lung Cancer 74: 35-40.
29. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, et al. (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131; 1190-1203.
30. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, et al. (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27: 4702-11.
31. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, et al. (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97: 643-55.
32. Di Fiore F, Sesboüé R, Michel P, Sabourin JC, Frebourg T, (2010) Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. Br J Cancer 103: 1765-72.
33. Garraway LA, Janne PA, (2012) Circumventing Cancer Drug Resistance in the Era of Personalized Medicine. Cancer Discovery 2;210-226.
34. Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, et al. (2006) Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res 12; 4103-11.
35. Guix M, Faber AC, Wang SE, Olivares MG, Song Y, et al. (2008) Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 118: 2609-19.
36. Gong Y, Yao E, Shen R, Goel A, Arcila M, et al. (2009) High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One. 4; e7273.
37. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
38. Kang S, Bader AG, Vogt PK, (2005) Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A 102; 802-7.
39. Ikenoue T, Kanai F, Hikiba Y, Obata T, Tanaka Y, et al. (2005) Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 65; 4562-7.